Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Developing MRD as an early endpoint for accelerated approval in CLL

Seminars in Hematology(2025)10.1053/j.seminhematol.2026.03.008Source: DataRank Database

Developing MRD as an early endpoint for accelerated approval in CLL is a research paper published in Seminars in Hematology (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: greenTopics (10)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

William G. Wierda ORCID,Jacob D. Soumerai ORCID

Live enrichment

PubMed:41986213 PMC:PMC13308830

NCI NIH HHS

Grant: P30 CA016672

NIH HHS

Grant: K08CA270202

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13308830/

publisherhttps://api.elsevier.com/content/article/PII:S0037196326000193?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0037196326000193?httpAccept=text/plain

MeSH Terms

HumansNeoplasm, ResidualPrognosisEndpoint DeterminationLeukemia, Lymphocytic, Chronic, B-Cell

Keywords

Chronic Lymphocytic LeukemiaCllEndpointMrdMeasurable Residual Disease